



Important Provider Notice



November 1, 2022

PA Medicare Policy Updates Effective December 1, 2022

An Update for Medicare Providers and Clinicians

Annually Reviewed Medical Policies with Changes

MP-044-MC-PA Pharmacogenomic Testing for Warfarin Response (NCD 90.1)

No changes to clinical criteria. Updated CMS hyperlinks, added LCA & related LCD hyperlinks. Corrected CPT code 31355 code description. Updated 'Reference Sources' section.

MP-035-MC-PA Testing for Genetic Disease

No changes to clinical criteria. Removed the following repetitive statement from the 'Procedure' section: "*The information from the genetic testing is expected to make an impact on the patient's treatment plan or the responsible family member/legal guardian intends to use the information in making decisions about his/her care or treatment plan*". Removed the word 'covered', replaced with 'medically necessary'. Added related CMS hyperlinks. Updated 'Summary of Literature' and 'Reference Sources' sections.

Annually Reviewed Medical Policies without Changes

MP-098-MC-PA Osteogenic Stimulators (150.2)

No changes to clinical criteria. Updated CMS hyperlinks. Updated 'Reference Sources' section.

Retired Policies

MP-038-MC-PA Glucose Monitors (L33822)

Policy to be retired, clinical criteria is imbedded within Medicare InterQual for this service.

Health benefits or health benefit administration may be provided by or through Highmark Wholecare, coverage by Gateway Health Plan, an independent licensee of the Blue Cross Blue Shield Association ("Highmark Wholecare").